Lucerna

Executive Summary

Lucerna Technologies is a Cambridge-based biotechnology company pioneering RNA visualization and targeting tools using its proprietary Spinach™ aptamer technology. Founded in 2019, the company develops fluorescent sensors and high-throughput screening assays that enable real-time RNA tracking in living cells, with primary applications in oncology and antiviral drug discovery. Lucerna's product portfolio includes fluorophores, custom sensor development services, and assays designed to accelerate RNA-focused research. Despite being privately held with limited public financial data, the company occupies a unique niche at the intersection of RNA biology and drug discovery, addressing a critical need for tools to study RNA dynamics in disease. Lucerna's platform has the potential to enhance target identification and validation for RNA therapeutics, a rapidly growing field. The company's technology is particularly relevant as RNA-based drugs gain traction, offering researchers the ability to visualize RNA localization, stability, and interactions in real time. While operating in a competitive landscape with other RNA tool providers, Lucerna's Spinach technology differentiates through its ability to function in live cells without genetic engineering. The company is well-positioned to capture value from the expanding RNA research market, though near-term revenue visibility remains limited as it continues to develop and commercialize its platform. Strategic partnerships with pharmaceutical companies and academic institutions could drive adoption and validate the technology, positioning Lucerna for future growth.

Upcoming Catalysts (preview)

• Q4 2026Strategic Partnership with a Top Pharma for RNA-Targeted Drug Discovery35% success
• Q2 2026Launch of Next-Generation Spinach-Based High-Throughput Screening Assay50% success
• Q3 2026Publication of Key Proof-of-Concept Data in a Tier-1 Journal40% success